- Reports: ESI may start 'price war' over new hepatitis C drugs
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Could ESI block Sovaldi from its formulary?
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
RIDGEFIELD, Conn. — Drug maker Boehringer Ingelheim has created a website designed for patients with hepatitis C and advocates, the company said Friday.
BI announced the launch of HepCRedefined.com, which it describes as an online portal to help improve the lives of those living with the virus through education, information and understanding.
"The entire HCV community is in need of simple tools and resources to talk about the disease in an informed, supportive way," said Hepatitis Education Project executive director Michael Ninburg, who contributed to the website's development. "There is information about HCV across the web, but HepCRedefined.com is designed to aggregate straightforward and accurate information in a single virtual destination."